Jade Therapeutics to use BioTime technology for sustained-release ophthalmic drugs
This article was originally published in Scrip
Executive Summary
Alameda, California-based stem cell technology developer BioTime entered into an exclusive sublicense and supply agreement for its HyStem hydrogels and certain other patented technologies with Jade Therapeutics of Salt Lake City, Utah, which is developing a sustained-release drug delivery platform for ophthalmic indications.